Aardvark Therapeutics, Inc.
AARD
$6.41
-$0.16-2.44%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 141.28% | 136.60% | 154.32% | 127.74% | 75.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.00% | 140.38% | 175.29% | 243.47% | 235.02% |
| Operating Income | -81.00% | -140.38% | -175.29% | -243.47% | -235.02% |
| Income Before Tax | -90.76% | -152.05% | -179.73% | -252.14% | -211.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.76% | -152.05% | -179.73% | -252.14% | -211.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.76% | -152.05% | -179.73% | -252.14% | -211.10% |
| EBIT | -81.00% | -140.38% | -175.29% | -243.47% | -235.02% |
| EBITDA | -81.02% | -140.38% | -175.31% | -300.93% | -395.54% |
| EPS Basic | 29.93% | 39.28% | 42.96% | -22.79% | -54.17% |
| Normalized Basic EPS | 29.38% | 38.96% | 42.36% | -23.33% | -60.20% |
| EPS Diluted | 29.93% | 39.28% | 42.96% | -22.79% | -54.17% |
| Normalized Diluted EPS | 29.38% | 38.96% | 42.36% | -23.33% | -60.20% |
| Average Basic Shares Outstanding | 103.00% | 245.07% | 390.33% | 281.82% | 170.65% |
| Average Diluted Shares Outstanding | 103.00% | 245.07% | 390.33% | 281.82% | 170.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |